Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.
Arexvy by GlaxoSmithKline Biologicals S.A. has been authorised for use in the European Union for Respiratory Syncytial Virus infections.
-
CLINICAL_TRIALS trial_result · 2026-08-20Clinical Trial Update: A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults [Phase 3]
Phase 3 trial update for mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in high-risk adults has completed.
-
CLINICAL_TRIALS trial_result · 2026-08-19Clinical Trial Results: A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. [Phase 2]
Phase 2 trial results for EDP-938 in non-hospitalized adults with RSV at high risk for complications have been completed with results posted…
-
CLINICAL_TRIALS trial_result · 2026-08-03Clinical Trial Results: A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of three dose concentrations of an RSV vaccine in infants and toddlers; study terminated …
-
EMA approval · 2026-07-21EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection [Phase 2]
Phase 2 trial results for Obeldesivir in children with RSV infection have been terminated; results posted.
-
EMA approval · 2026-06-04EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited
The EMA authorises Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use in Respiratory Syncytial Virus vaccines.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose [Phase 3]
A Phase 3 trial evaluating revaccination in subsequent pregnancies with a bivalent RSV vaccine and the duration of protection from a single …
-
EMA approval · 2026-04-24EMA Authorised: Beyfortus (nirsevimab) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Beyfortus (nirsevimab) for prevention of respiratory syncytial virus infection in infants, with mar…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products [Phase 4]
Phase 4 clinical trial update evaluating the immunology and safety of maternal RSV vaccination ABRYSVO and infant nirsevimab BEYFORTUS, alon…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) [Phase 2]
Phase 2 clinical trial update for PUL-042 in patients with parainfluenza virus, human metapneumovirus, or respiratory syncytial virus infect…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV [Phase 1]
An update on a Phase 1 trial evaluating JCXH-108, an mRNA-based vaccine for respiratory syncytial virus (RSV) infection, developed by Immorn…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older [Phase 1]
A Phase 1 study of a vaccine candidate against respiratory syncytial virus, metapneumovirus, and parainfluenza virus type 3 in adults aged 6…
-
EMA approval · 2026-04-22EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited
The European Medicines Agency authorised Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use against Respiratory Syncytial Viru…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. [Phase 3]
Pfizer's RSVpreF Phase 3 study aims to evaluate safety and immune response in adults at high risk for severe Respiratory Syncytial Virus inf…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease [Phase 3]
Phase 3 clinical trial update for a vaccine against respiratory syncytial virus being tested in Chinese adults at increased risk, currently …
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease [NA]
AstraZeneca is evaluating palivizumab for prevention of severe respiratory syncytial virus disease in high-risk children. The study is curre…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab [Phase 3]
A Phase 3 study evaluating safety, pharmacokinetics, anti-drug antibodies, and anti-RSV antibodies after two doses of nirsevimab has complet…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults [Phase 1]
This document describes a Phase 1 clinical trial to assess the safety and immunogenicity of the IN006 respiratory syncytial virus vaccine in…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: RSV Vaccination to Reduce Recurrent AECOPD [Phase 4]
A Phase 4 clinical trial led by the Chinese University of Hong Kong is evaluating an RSV vaccine to reduce recurrent acute exacerbations of …
-
EMA approval · 2026-04-10EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
The EMA authorised Abrysvo, Pfizer's bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections in the E…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age [Phase 1]
A Phase 1 clinical trial in adults 18-49 is evaluating two vaccine formulations encoding the RSV monovalent antigen or the influenza A(H5) a…
-
FDA approval · 2026-04-07FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
FDA approved a supplemental application for Beyfortus (nirsevimab) submitted by Sanofi Vaccines US Inc.
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above [Phase 1]
This clinical trial update summarizes a Phase 1 study assessing the safety and immunogenicity of the IN006 RSV vaccine in healthy adults age…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children [Phase 3]
A Phase III clinical trial is evaluating deuremidevir hydrobromide for treating respiratory syncytial virus infection in infants and young c…